Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investigator-Initiated Nonrandomized Clinical Trial.
Sign Up to like & getrecommendations! Published in 2023 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2022.7975
Abstract: Importance To our knowledge, this is the first clinical trial designed to investigate concurrent treatment with a checkpoint inhibitor and conventional chemotherapy in relapsed or refractory classic Hodgkin lymphoma in patients destined for an autologous… read more here.
Keywords: hodgkin lymphoma; relapsed refractory; refractory classic; chemotherapy ... See more keywords
Phase 2 study of MK-3475A in relapsed or refractory classic Hodgkin lymphoma or primary mediastinal large B-cell lymphoma.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.tps7090
Abstract: TPS7090 Background: The PD-1 inhibitor pembrolizumab is approved globally for the treatment of multiple cancers, including relapsed or refractory (R/R) classic Hodgkin lymphoma (cHL) and R/R primary mediastinal large B-cell lymphoma (PMBCL). Pembrolizumab is currently… read more here.
Keywords: pembrolizumab; refractory classic; cell; lymphoma ... See more keywords